1. Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib
- Author
-
Kai Deng, Qiongqiong Li, Lina Lu, Luting Wang, Zhiyong Cheng, and Suyun Wang
- Subjects
Computer-aided drug discovery ,Fluzoparib ,Multi-target drug ,Multiple myeloma ,Poly(ADP-Ribose) polymerase ,Biology (General) ,QH301-705.5 ,Biochemistry ,QD415-436 - Abstract
One of the current mainstream treatments for multiple myeloma (MM) is chemotherapy. However, due to the high clonal heterogeneity and genomic complexity of MM, single-target drugs have limited efficacy and are prone to drug resistance. Therefore, there is an urgent need to develop multi-target drugs against MM. We screened drugs that simultaneously inhibit poly(ADP-ribose) polymerase 1 (PARP1) and 20S proteasome through computer-aided drug discovery (CADD) techniques, and explored the binding mode and dynamic stability of selected inhibitor to proteasome through Molecular biology (MD) simulation method. Thus, the dual-target inhibition effect of fluzoparib was proposed for the first time, and the ability of dual-target inhibition and tumor killing was explored at the enzyme, cell and animal level, respectively. This provides a theoretical and experimental basis for exploring multi-target inhibitory drugs for cancers.
- Published
- 2024
- Full Text
- View/download PDF